ATHENAGEN ADVANCES ATG002 TO CLINICAL TRIALS

Athenagen has completed preparation for a Phase I/II clinical trial of its pro-angiogenesis topical wound healing agent ATG002.

Earlier this year the company filed an investigational new drug application with FDA for ATG002, a topical nicotinic acetylcholine (nACh) receptor agonist, to study the drug in patients with diabetic foot ulcers. The Phase I/II safety and proof-of-concept study will be conducted at leading wound care clinical sites in the U.S.